ANR analyst downgrade coming, possible bankruptcy chapter 11 reorganization.
This looks to be a money loser for at least 3 years probably trade down to $3 a share when people realize this company has burned through its cash and earnings might be $.10 a year for the next five years....
Sentiment: Strong Sell
ANR Bankrupt? Trying to piece together the balance sheet...lots of holes
If I calculated right they are out of cash Friday unless they raised money somehow!!!!! Anyone else calc out burn rate?????
Sentiment: Strong Sell
i see all the shorts are hedge funds in NY, CT and Chicago!!!
You going to get a little lesson from us Okies and Texans on this one!
Should see a minimum 2 bcf/day shut in until winter....if it reaches cat 3, could be up to 5-6bcf/day less.....Nat Gas could easily pop to $4-$5 before new rigs get deployed for production. This is major bullish development through Q1 2013.
That is if Isaac lands between new orleans and mobile bay......gulfport, Miss.?????
Median Survival is longer now, the MEdian Survival quoted is from 2005 in the data results...So those statistics though won't harm the efficacy it could raise the potential of not as great of an outcome in the phase II results if updated median survival data is used.
Polyana CEO saying things are great...then resigns..might sue next week
I think this trades $1 tomorrow and not much better until results>
I still shares to sell
I guess now we know it all depends on Phase II data. stock worth $.50 or $30.
Bad timing for new shareholders.....I got f'ed down over $200k on this investment. Had 220,000 shares and own a bunch of February $5 calls .....dumped 150,000 shares during market hours today and another 60,000 after market....what a POS deal this turned out to be.....
"We are pleased that FDA has recognized the potential that ICT-107 has to treat GBM and has granted us orphan drug status”, said ImmunoCellular Therapeutics’ president and CEO said Manish Singh, Ph.D. "The designation should facilitate a shorter time period to approval and reflects the FDA’s views on the importance of developing a treatment which will improve survival outcomes for those afflicted with this terrible disease."
The 12-month disease-free survival from the time of surgery was 75% with ICT-107, compared with a historical control survival rate of 26.9%, and the 18-month disease-free survival with ICT-107 was 49.2%, compared with 18.4% historically. Safety data for ICT-107 also compared favorably to current treatments: no serious adverse events were reported and minor side effects were limited to fatigue, skin rash and pruritis.
Also read on another blog....Initiate European Approvals for ICT 107
BY Business Wire
— 7:00 AM ET 08/15/2012
LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics, Ltd. (IMUC
) (“ImmunoCellular” or the “Company”), today announced second quarter results for the period ended June 30, 2012.
Highlights of the second quarter and recent weeks include:
Ended second quarter with $11.3 million cash, sufficient to fund next 12 months of operations
Qualified and listed on the NYSE MKT
Added to the Russell 3000®, Global and Microcap Indexes
Clinical and Business Highlights:
ICT-107 Phase I clinical data was accepted for publication in prestigious peer-reviewed medical journal: Cancer Immunology, Immunotherapy
Expanded enrollment of Phase II clinical trial of ICT-107
Presented long-term survival data from Phase I study of ICT-107 at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Brought online second manufacturing site for ICT-107 at a facility run by Progenitor Cell Therapy (PCT)
FDA clearance of new IND application for Phase I trial of ICT-121
Received important Japanese patent relating to technology for the treatment of brain cancer
The Company incurred $3.1 million in the quarter to support research and development activities and for general operations. Net loss for the quarter of approximately $6.5 million, or $0.16 per basic and diluted share, included an expense for the change in fair value of its warrant liabilities of $3.3 million primarily driven by the increase in the Company’s stock price.
ImmunoCellular Therapeutics, Ltd. (IMUC
) Chief Executive Officer Manish Singh commented, “We are pleased by the progress in our Phase II clinical trial of ICT-107. We look forward to continuing to work closely with the investigators and trial sites to complete enrollment and to obtaining patient data.”